Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
Int J Mol Sci
; 21(22)2020 Nov 16.
Article
en En
| MEDLINE
| ID: mdl-33207738
ABSTRACT
USP7 is a promising target for the development of cancer treatments because of its high expression and the critical functions of its substrates in carcinogenesis of several different carcinomas. Here, we demonstrated the effectiveness of targeting USP7 in advanced malignant cells showing high levels of USP7, especially in taxane-resistant cancer. USP7 knockdown effectively induced cell death in several cancer cells of lung, prostate, and cervix. Depletion of USP7 induced multiple spindle pole formation in mitosis, and, consequently, resulted in mitotic catastrophe. When USP7 was blocked in the paclitaxel-resistant lung cancer NCI-H460TXR cells, which has resistance to mitotic catastrophe, NCI-H460TXR cells underwent apoptosis effectively. Furthermore, combination treatment with the mitotic kinase PLK1 inhibitor volasertib and the USP7 inhibitor P22077 showed a strong synergism through down-regulation of MDR1/ABCB1 in paclitaxel-resistant lung cancer. Therefore, we suggest USP7 is a promising target for cancer therapy, and combination therapy with inhibitors of PLK1 and USP7 may be valuable for treating paclitaxel-resistant cancers, because of their strong synergism.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pteridinas
/
Tiofenos
/
Proteínas Proto-Oncogénicas
/
Paclitaxel
/
Proteínas Serina-Treonina Quinasas
/
Proteínas de Ciclo Celular
/
Resistencia a Antineoplásicos
/
Peptidasa Específica de Ubiquitina 7
/
Neoplasias
Límite:
Humans
Idioma:
En
Año:
2020
Tipo del documento:
Article